Insider Transactions in Q1 2024 at Gilead Sciences, Inc. (GILD)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
846
-5.79%
|
$63,450
$75.12 P/Share
|
|
Mar 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
2,555
+14.89%
|
-
|
|
Mar 10
2024
|
Sandra Patterson SVP, Controllership |
SELL
Payment of exercise price or tax liability
|
Direct |
790
-2.36%
|
$59,250
$75.12 P/Share
|
|
Mar 10
2024
|
Sandra Patterson SVP, Controllership |
BUY
Exercise of conversion of derivative security
|
Direct |
2,682
+3.9%
|
-
|
|
Mar 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,782
-2.76%
|
$1,033,650
$75.12 P/Share
|
|
Mar 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
29,940
+2.95%
|
-
|
|
Mar 10
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,803
-4.66%
|
$360,225
$75.12 P/Share
|
|
Mar 10
2024
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,401
+4.89%
|
-
|
|
Mar 10
2024
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,505
-3.23%
|
$337,875
$75.12 P/Share
|
|
Mar 10
2024
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,732
+3.41%
|
-
|
|
Mar 10
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,559
-3.71%
|
$341,925
$75.12 P/Share
|
|
Mar 10
2024
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,844
+3.9%
|
-
|
|
Feb 29
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,230
-8.15%
|
$592,560
$72.74 P/Share
|
|
Feb 28
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,000
-1.94%
|
$146,000
$73.18 P/Share
|
|
Feb 02
2024
|
Ted W Love Director |
BUY
Grant, award, or other acquisition
|
Direct |
512
+50.0%
|
-
|
|
Jan 31
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
23,709
-18.77%
|
$1,849,302
$78.26 P/Share
|
|
Jan 31
2024
|
Merdad Parsey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
76,853
+26.72%
|
-
|
|
Jan 31
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,509
-16.59%
|
$1,755,702
$78.26 P/Share
|
|
Jan 31
2024
|
Johanna Mercier Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,055
+24.1%
|
-
|
|
Jan 31
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Grant, award, or other acquisition
|
Direct |
4,646
+28.37%
|
-
|
|
Jan 31
2024
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
23,410
-15.32%
|
$1,825,980
$78.26 P/Share
|
|
Jan 31
2024
|
Andrew D Dickinson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,961
+21.6%
|
-
|
|
Jan 31
2024
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
79,335
-14.48%
|
$6,188,130
$78.26 P/Share
|
|
Jan 31
2024
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
230,747
+18.43%
|
-
|
|
Jan 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
194
-2.67%
|
$15,520
$80.23 P/Share
|
|
Jan 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
514
+6.6%
|
-
|
|
Jan 16
2024
|
Andrew D Dickinson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.69%
|
$425,000
$85.78 P/Share
|
|
Jan 09
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
8,242
-9.06%
|
$700,570
$85.23 P/Share
|